Idenix Pharmaceuticals (IDIX) starts patient enrollment in HELIX-2 — that's the DAA HCV combo comprising samatasvir and the JNJ co-developed protease inhibitor and polymerase inhibitor simeprevir and TMC647055.
The Phase 2 study will evaluate efficacy, safety and tolerability of the combo in treatment-naïve or relapsed (after interferon and ribavirin) GT1 HCV patients. (PR)
In other company news, IDIX has filed two patent infringement lawsuits against Gilead (GILD) tied to methods of treating the HCV using 2'-methyl nucleosides.
Here's IDIX: "[The company] is seeking a declaration that GILD's imminent distribution, importation, use, sale or offer to sell drugs containing sofosbuvir, a 2'-methyl nucleoside compound, infringes IDIX's patents." (PR)